Browse the evidence

Achieving diabetes remission in type 2 diabetes patients reduces the risk of cardiovascular disease by approximately 30% compared to non-remission, independent of significant weight loss.

For patients with type 2 diabetes, achieving remission (normal blood glucose without medication) is a critical goal for preventing heart disease. This benefit exists even if you do not lose significant weight, suggesting that metabolic improvements (like reduced liver/pancreas fat) are key. Focus on achieving remission through available treatments rather than solely on weight loss metrics.

When resistance training is performed to volitional fatigue, muscle hypertrophy is independent of the external load used (high vs. low), provided volume load is matched or effort is equivalent.

You do not need to lift heavy weights to build muscle. If you use lighter weights (30-40% of your max), you must perform more reps (20-25) and push until you physically cannot complete another rep with good form. This effort-to-failure approach yields the same muscle growth as heavy lifting (70-80% max) done for fewer reps (8-12). Ensure you eat enough protein (at least 1.6g per kg of body weight) and train consistently 3 times a week.

Using lean body mass (LBM) and body fat percentage (BF) in reference equations for peak oxygen uptake (VO2peak) provides better calibration for overweight and obese individuals compared to equations based on total body mass.

If you are overweight or obese, standard fitness tests that use your total body weight to predict your maximum oxygen uptake (VO2peak) likely overestimate your fitness level. To get an accurate assessment of your cardiorespiratory health, especially if you are older, use reference equations that account for your lean body mass and body fat percentage. This prevents being falsely categorized as 'fit' when your actual functional capacity may be lower.

Long-term caloric restriction (25% reduction for 24 months) induces metabolic adaptation (adaptive thermogenesis) in sleeping energy expenditure that exceeds predictions based on changes in body mass alone, with the effect persisting at 24 months when assessed using advanced MRI-derived organ and tissue mass models.

If you restrict calories by 25% for two years, your body will adapt by lowering its energy expenditure more than expected from weight loss alone. This 'metabolic adaptation' is real and persists, especially when looking at organ-level changes. To manage this, focus on preserving muscle mass through resistance training and protein intake, as the study shows lean tissue loss is part of the equation, though not the whole story of metabolic slowdown.

Habitual endurance or resistance exercise training enhances insulin-stimulated glycogen synthesis in primary human skeletal muscle stem cells compared to sedentary controls, but does not confer intrinsic protection against fatty acid-induced insulin resistance.

If you are highly active, your skeletal muscle cells are better at storing glucose as glycogen when insulin is present, regardless of whether you primarily do cardio or weight training. However, this cellular adaptation does not appear to protect your muscle cells from the negative effects of high fat exposure in a lab setting. To maximize metabolic health, maintain high activity levels, but be aware that cellular adaptations to training may not fully shield you from all metabolic insults like high lipid loads.

Hypercaloric 16:8 time-restricted eating (TRE) allows well-trained individuals to achieve similar gains in fat-free mass and strength as continuous feeding (FED) during resistance training, despite a reduction in total training volume.

If you are already training regularly and want to build muscle, you can compress your eating into an 8-hour window without losing gains, as long as you eat enough total calories (a slight surplus) and hit your protein targets (around 2.2g/kg). You might train slightly less volume, but your strength and muscle mass will still increase similarly to eating throughout the day. Focus on consistency and total intake, not just when you eat.

While fat-free mass gains are similar, 16:8 TRE results in less fat mass accumulation and lower total training volume compared to continuous feeding during a caloric surplus.

Be aware that if you switch to an 8-hour eating window, you might naturally train for less total volume and accumulate slightly less fat than if you ate all day, even in a surplus. This isn't necessarily bad—it might mean you are more efficient with your energy—but it is a trade-off to consider if your goal is maximum fat gain (bulking).

Treatment with maximal-tolerated dose tirzepatide (10-15 mg weekly) for 72 weeks produces substantial weight loss and health risk reduction, but typically fails to return average Class II obese individuals to the healthy BMI (<25 kg/m2) or healthy Body Roundness Index (BRI) ranges.

If you are taking tirzepatide at a high dose, expect significant health improvements and weight loss, but do not expect to automatically reach a 'healthy' BMI of under 25. The average patient in the major trials remains in the overweight or obese category even after a year. Focus on the reduction in health risks (like visceral fat/BRI) rather than just hitting a specific BMI number.

Semaglutide 2.4 mg weekly significantly improves symptoms, functional capacity, and reduces systemic inflammation in obese patients with heart failure with preserved ejection fraction (HFpEF).

If you have heart failure with preserved ejection fraction and are obese, ask your doctor about semaglutide. It is a once-weekly injection that has been shown to significantly improve your heart failure symptoms, exercise capacity, and reduce inflammation. While it may cause temporary stomach issues, the benefits for your heart and weight are substantial.

Genetic variation in the NBEA gene predicts weight loss response to GLP-1 receptor agonists (GLP-1RAs), with specific NBEA scores identifying individuals likely to be highly responsive or non-responsive to treatment.

If you are prescribed a GLP-1RA like semaglutide or liraglutide, ask your doctor about genetic testing for the NBEA gene. This test can predict whether you are likely to lose significant weight (top 20% responders) or not respond at all. This helps avoid wasting time and money on medications that are unlikely to work for your specific biology, allowing for a more personalized and effective obesity treatment plan.

Achieving ≥20–25% early postoperative weight loss (EWL) within the first 3–6 months after bariatric surgery strongly predicts sustained long-term weight loss (≥50% EWL) and metabolic remission.

If you had bariatric surgery, your weight loss in the first 3-6 months is a major predictor of your long-term success. Aim for at least 20-25% excess weight loss in this window. If you are slower, do not give up; this is a signal for your medical team to intensify support (nutrition, behavioral therapy, or medication) to help you catch up.

Semaglutide 2.4 mg is recommended for secondary prevention of cardiovascular events in individuals with BMI ≥27 kg/m² without diabetes but with established cardiovascular disease.

If you have established heart disease, are overweight (BMI ≥27), and do not have diabetes, ask your doctor about semaglutide 2.4 mg. This medication is recommended to help prevent future heart attacks, strokes, and cardiovascular death.

Caloric restriction interventions restore gut-brain axis communication in obesity by enriching beneficial bacteria (e.g., Akkermansia muciniphila), reducing LPS-mediated endotoxemia, and modulating SCFA production to enhance satiety signaling.

To leverage the gut-brain axis for weight management, reduce your daily caloric intake by 20-40% while ensuring you get adequate nutrients. This specific type of dietary restriction has been shown to improve gut bacteria diversity, reduce inflammation, and boost satiety hormones, making it easier to maintain energy balance.

Obesity is associated with gut microbiota dysbiosis characterized by reduced diversity, altered taxonomic abundance, and impaired gut-brain axis communication, leading to dysregulated appetite and energy homeostasis.

Obesity is linked to changes in gut bacteria that disrupt signals for hunger and fullness. These changes include lower bacterial diversity and reduced production of satiety hormones. Understanding this link highlights why dietary changes can help reset these signals.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors reduce cardiovascular events and improve liver histology in MASLD patients, particularly those with type 2 diabetes or obesity.

If you have MASLD and diabetes or obesity, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT2 inhibitors. These drugs not only help control blood sugar and weight but also significantly lower the risk of heart attacks and strokes, and may improve liver health. They are safe for use in MASLD patients within their approved indications.

Excess adiposity (BMI ≥30) is a causal risk factor for gastrointestinal cancers, increasing incidence and mortality through endocrine, inflammatory, and mechanical pathways.

Maintain a healthy weight to reduce your risk of gastrointestinal cancers. If you are overweight, consult your doctor about structured weight loss strategies, as obesity increases cancer risk and complicates surgical outcomes.

Obesity increases perioperative morbidity and technical complexity in gastrointestinal cancer surgery, including higher rates of anastomotic leak and surgical site infection.

If you are obese and undergoing gastrointestinal cancer surgery, discuss the increased risk of complications with your surgeon. Preoperative weight loss may be recommended to reduce these risks.

Semaglutide significantly reduces the risk of atrial fibrillation (AF) and sinus node dysfunction in patients with overweight or obesity.

If you have overweight or obesity and are concerned about heart rhythm issues like atrial fibrillation, semaglutide therapy (up to 2.4 mg) has been shown in large studies to significantly lower that risk. This benefit appears particularly strong in patients over 60 and those treated for more than a year.

Semaglutide significantly reduces the risk of acute myocardial infarction and angina pectoris in patients with overweight or obesity, with greater efficacy observed in patients over 60 years and those treated for more than 52 weeks.

For patients with overweight or obesity, semaglutide (up to 2.4 mg) significantly lowers the risk of heart attacks and angina. This benefit is particularly pronounced in patients over 60 years old and those who maintain treatment for more than one year, suggesting that long-term adherence is key to maximizing cardiovascular protection.

Electronic health record (EHR) data from the one-year period prior to initiating anti-obesity medication (AOM) contains sufficient multidimensional clinical signals to identify distinct obesity subtypes (clusters) with unique physiological profiles, enabling precision medicine approaches that outperform traditional BMI-based classifications.

If you are considering obesity medication, ask your doctor about 'deep phenotyping.' This means using your full medical history (labs, vitals, diagnoses) from the past year to group you into a specific 'obesity subtype.' This helps predict which medication will work best for you, rather than just using your BMI. It reduces the guesswork in choosing between different drugs like GLP-1 agonists or others.

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) significantly improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, though they carry a risk of lean mass loss.

If you have HFpEF and obesity, GLP-1/GIP medications like semaglutide or tirzepatide can significantly improve your heart health, symptoms, and quality of life. To counteract potential muscle loss, you must combine these medications with resistance training and high protein intake. Discuss these options with your cardiologist, as they are increasingly recognized as effective treatments for this specific heart condition.

Tirzepatide reduces liver fat content and visceral adipose tissue in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and are concerned about liver health, tirzepatide not only helps control blood sugar and weight but also significantly reduces liver fat, which is beneficial for overall metabolic health.

Resmetirom (80-100 mg daily) significantly improves MASH resolution and fibrosis regression in patients with F2-F3 fibrosis compared to placebo.

If you have moderate-to-advanced liver scarring from MASH, resmetirom is the first approved drug to help reverse it. Take 80mg or 100mg daily. Expect possible mild stomach issues, but serious risks are low. This targets the root hormonal imbalance driving liver fat.

GLP-1 receptor agonists (e.g., Semaglutide) improve MASH indirectly through weight loss and improved insulin resistance, as the liver lacks direct GLP-1 receptors.

GLP-1 drugs like Semaglutide help MASH by making you lose weight and improving insulin sensitivity, not by acting directly on the liver. They are approved for obesity and diabetes and show strong benefits for liver health through these indirect pathways.